New HIV prevention option: a douche that protects?

NCT ID NCT06560684

Ongoing Prevention Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) Source: ClinicalTrials.gov ↗

First seen Jan 16, 2026 · Last updated May 22, 2026 · Updated 15 times

Summary

This study tests a new way to prevent HIV using a rectal gel (tenofovir douche) instead of taking pills. About 150 men will try both methods for 8 weeks each to see which is safer, easier to use, and more acceptable. The goal is to offer more choices for on-demand HIV prevention.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TENOFOVIR are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Alabama CRS (Site ID# 31788)

Birmingham, Alabama, 35222, United States
Chapel Hill CRS (3201)

Chapel Hill, North Carolina, 27599-7215, United States
Fenway Health (FH) CRS

Boston, Massachusetts, 02215-4302, United States
Hope Clinic CRS

Lawrenceville, Georgia, 30046, United States
Johns Hopkins University CRS

Baltimore, Maryland, 21287, United States
UCLA CARE Center CRS

Los Angeles, California, 90035, United States
University of Pittsburgh CRS

Pittsburgh, Pennsylvania, 15213, United States
Weill Cornell Chelsea CRS

New York, New York, 10011, United States

Conditions

Explore the condition pages connected to this study.

TENOFOVIR